Findings from a large randomized clinical trial of household contacts helped get oral ensitrelvir approved for COVID-19 post-exposure prophylaxis in the U.S. and Japan.
The department confirmed that the authorization granted on June 11 makes Zepbound the only GLP-1 drug in Canada approved for the sleep disorder that causes people to stop breathing temporarily because their upper airway is blocked.
Based on recent guidance from the National Advisory Committee on Immunization, all of the following are strongly recommended to receive TWO doses of COVID-19 vaccine per year, EXCEPT for . . .
Study investigates the association between oral corticosteroid use and systemic adverse events in patients with chronic rhinosinusitis with nasal polyps.
Parent advocates have been urging changes to a policy that sets out responsibilities of school boards, principals and staff when it comes to children with anaphylaxis, asthma, diabetes and epilepsy.
A group of Canadian researchers says the amount of powdery pollen released by plants during their reproduction process has gone up across Canada in recent years and is exacerbating allergies from hay fever to hives.
